Ghrelin-receptor agonist (GHRP)
Hexarelin
Potent GHS-R1a ; experimental cardiac GHS-R effects have been studied separately from GH release.
Primary Mechanism of Action
Clinical / Scientific
Hexarelin is a hexapeptide secretagogue at GHS-R1a with robust GH release. Preclinical cardioprotective GHS-R signalling has been reported; that is not an approved cardiac indication.
Pathway Targets
GHS-R1a
Scientific explanation
Pituitary GH release and extra-pituitary ghrelin- signalling.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: GHS-R1a
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| GHS-R1a | Agonism | GH secretion; experimental cardiac signalling | Established GH mechanism; cardiac data preclinical |
In Plain Language
Hexarelin is a strong ghrelin- peptide for growth-hormone release. Heart-related findings are still experimental.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
GHS-R1a
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.